Anzeige
Mehr »
Login
Freitag, 08.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 854943 | ISIN: BE0003565737 | Ticker-Symbol: KDB
Tradegate
08.11.24
11:20 Uhr
69,74 Euro
-0,16
-0,23 %
1-Jahres-Chart
KBC GROEP NV Chart 1 Jahr
5-Tage-Chart
KBC GROEP NV 5-Tage-Chart
RealtimeGeldBriefZeit
68,7268,7415:33
68,7068,7415:32
GlobeNewswire (Europe)
177 Leser
Artikel bewerten:
(1)

KBC Groep: Third-quarter result of 868 million euros


KBC Group - overview (consolidated, IFRS)
3Q20242Q20243Q20239M20249M2023
Net result (in millions of EUR)8689258772 3002 725
Basic earnings per share (in EUR)2.142.252.075.586.44
Breakdown of the net result by business unit (in millions of EUR)
Belgium5985195171 3591 392
Czech Republic179244200620661
International Markets205224200576498
Group Centre-114-61-41-255174
Parent shareholders' equity per share (in EUR, end of period)54.153.252.254.152.2

We recorded a net profit of 868 million euros in the third quarter of 2024. Compared to the result for the previous quarter, our total income benefited from several factors, including higher net interest income (despite significantly lower income on inflation-linked bonds), increased insurance revenues supported by commercial actions, and higher net fee and commission income driven by excellent business performance. These items were offset by a decrease in trading & fair value income and the drop in dividend income following its seasonal peak in the second quarter.

Our loan portfolio continued to expand, increasing by 1% quarter-on-quarter and by 5% year-on-year. Customer deposits - excluding volatile, low-margin short-term deposits at KBC Bank's foreign branches - were up 3% quarter-on-quarter and 5% year-on-year. As regards Belgium, deposits grew by as much as 5% quarter-on-quarter and 8% year-on-year, owing to the successful recuperation of customer funds following the maturity of the Belgian state note issued a year earlier. In fact, thanks to our proactive, multi-phased and multi-product customer offering, the total inflow of core customer money after the state note matured amounted to 6.5 billion euros, outpacing last year's 5.7-billion-euro outflow to the state note by 0.8 billion euros.

Operational expenses were up in the quarter under review but remained perfectly within our full-year 2024 guidance. Insurance service expenses were higher, partly as a result of the storms and floods in Central Europe, especially Storm Boris. To date, we are helping some 10 000 customers alleviate the impact of the floods caused by this storm. Next to that, we established a donation fund. Loan loss impairment charges, excluding the reserve for geopolitical and macroeconomic uncertainties, were up on the level recorded in the previous quarter, leading to a credit cost ratio of 16 basis points for the first nine months of 2024, substantially below the guidance. Including the reserve for geopolitical and macroeconomic uncertainties, the credit cost ratio stood at 10 basis points for the first nine months of 2024. In the quarter under review, we also booked a one-off 79-million-euros gain, under 'share in results of associated companies & joint ventures'.

Our solvency position remained strong, with a fully loaded common equity ratio of 15.2% at the end of September 2024. Our liquidity position remained very solid too, as illustrated by an LCR of 159% and NSFR of 142%. As already announced earlier, we will - in line with our general dividend policy - pay an interim dividend of 1 euro per share on 14 November 2024 as an advance on the total dividend for financial year 2024.

The share of bank and insurance products sold digitally has continued to rise: based on a selection of core products, around 55% of our banking and 29% of our insurance products were sold through a digital channel, up from 51% and 26% a year ago. And Kate, our personal digital assistant, is making good progress too: to date, over 5 million customers have already used Kate, an increase of no less than 37% on the year-earlier figure, while the proportion of cases resolved fully autonomously by Kate continues to improve and now stands at 67% in Belgium and 69% in the Czech Republic. I'm also delighted to add that our successful digitalisation and innovation journey regularly receives recognition from external parties. I am particularly proud that, just a few weeks ago, the independent international research agency Sia Partners honoured us by naming KBC Mobile the best mobile banking app in the world.

Our ultimate aim is to be the reference bank-insurer in all our core markets. This ambition is fuelled by our customer-centric business model and, most importantly, by the trust our customers, employees, shareholders, and other stakeholders place in us. We appreciate and are deeply grateful for this continued trust.

Johan Thijs
Chief Executive Officer

Attachments

  • 3q2024-pb-en (https://ml-eu.globenewswire.com/Resource/Download/e4e07487-6bc1-46b6-9784-6e93d26762f6)
  • 3q2024-quarterly-report-en (https://ml-eu.globenewswire.com/Resource/Download/d827632d-5a66-41ff-a375-c4b3c70f6a96)

© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.